name,pdb_id,pubmed_id,resolution,uniprot,PFAM,CATH,receptor_chain,receptor_length,peptide_chain,peptide_length,sequence_alignment,stride,percent_exposed_alignment,cluster_number,binding_mode,size_of_binding_mode,core_ecr_alignment,longest_continuous_core,longest_continuous_ecr,corebinding_aa,exosite_aa,surface_aa,interior_aa,corebinding_ss,exosite_ss,surface_ss,interior_ss,unique_id,COREBINDING_aa,COREBINDING_ss,EXOSITE_aa,EXOSITE_ss,bfact,bs_loc_type,full_peptide_sequece,mean_seq_iden_in_bm,mean_seq_iden_not_bm,min_dist_E_C_diff_bm,occupancy,pep_loc_type,title
1OSV_B_E_39_2.pdb,1OSV,12718893,2.50,Q62735,PF00104,1.10.565.10,B,229,E,12,ENALLRYLLDKD,CCHHHHHHHCCC,401202201224,39,2,1,CCCCCCCCCCCC,12,0,E:0;F:0;K:0;L:0;P:0;Q:0;S:0;T:0,E:0;F:0;K:0;L:0;P:0;Q:0;S:0;T:0,A:2;D:7;E:8;F:1;G:1;H:2;I:1;K:8;L:1;M:1;N:1;P:2;Q:2;R:2;S:2;T:2;V:1;Y:2,A:12;C:3;D:5;E:15;F:9;G:5;H:6;I:14;K:6;L:29;M:7;N:5;P:6;Q:9;R:8;S:9;T:8;V:9;W:2;Y:5,C:0;H:0,C:0;H:0,C:9;G:2;H:23;T:12,C:14;G:1;H:134;T:23,39_2,E:1;F:1;K:1;L:1;P:1;Q:2;S:1;T:3,C:4;H:7,E:0;F:0;K:0;L:0;P:0;Q:0;S:0;T:0,C:0;H:0,764444434567,GLN_25_B_COREBINDING;GLN_54_B_COREBINDING;GLU_47_B_COREBINDING;LEU_222_B_COREBINDING;LYS_218_B_COREBINDING;PHE_219_B_COREBINDING;PRO_221_B_COREBINDING;SER_51_B_COREBINDING;THR_220_B_COREBINDING;THR_28_B_COREBINDING;THR_50_B_COREBINDING,ENALLRYLLDKD,-1,0.164127446223516,,999999999999,GLU_1_E_C;ASN_2_E_C;ALA_3_E_C;LEU_4_E_C;LEU_5_E_C;ARG_6_E_C;TYR_7_E_C;LEU_8_E_C;LEU_9_E_C;ASP_10_E_C;LYS_11_E_C;ASP_12_E_C,"STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF 2 THE NUCLEAR RECEPTOR FXR"
2BJ4_A_C_39_3.pdb,2BJ4,15728727,2.00,P03372,PF00104,1.10.565.10,A,218,C,11,LTSRDFGSWYA,CBGGGCCCCCC,11012011013,39,3,1,CCCCCCCCCCC,11,0,A:0;E:0;G:0;I:0;L:0;M:0;N:0;P:0;Q:0;R:0;V:0;W:0;Y:0,A:0;E:0;G:0;I:0;L:0;M:0;N:0;P:0;Q:0;R:0;V:0;W:0;Y:0,A:1;D:2;E:5;G:1;H:1;K:3;L:7;M:2;N:1;P:2;Q:1;S:5;T:1;V:1;Y:2,A:11;C:3;D:8;E:5;F:7;G:8;H:10;I:11;K:6;L:31;M:11;N:5;P:1;Q:7;R:7;S:11;T:8;V:9;W:2,B:0;C:0;E:0;H:0;T:0,B:0;C:0;E:0;H:0;T:0,C:8;G:2;H:21;T:4,C:11;E:8;G:4;H:126;T:12,39_3,A:1;E:4;G:1;I:1;L:4;M:1;N:1;P:3;Q:1;R:2;V:1;W:1;Y:1,B:1;C:7;E:1;H:10;T:3,A:0;E:0;G:0;I:0;L:0;M:0;N:0;P:0;Q:0;R:0;V:0;W:0;Y:0,B:0;C:0;E:0;H:0;T:0,77666667778,ALA_185_A_COREBINDING;ARG_195_A_COREBINDING;ARG_86_A_COREBINDING;ASN_131_A_COREBINDING;GLN_133_A_COREBINDING;GLU_135_A_COREBINDING;GLU_136_A_COREBINDING;GLU_19_A_COREBINDING;GLU_89_A_COREBINDING;GLY_134_A_COREBINDING;ILE_22_A_COREBINDING;LEU_132_A_COREBINDING;LEU_16_A_COREBINDING;LEU_181_A_COREBINDING;LEU_95_A_COREBINDING;MET_88_A_COREBINDING;PRO_20_A_COREBINDING;PRO_21_A_COREBINDING;PRO_98_A_COREBINDING;TRP_85_A_COREBINDING;TYR_24_A_COREBINDING;VAL_138_A_COREBINDING,LTSRDFGSWYA,-1,0.627485604179092,,99999999999,LEU_1_C_C;THR_2_C_C;SER_3_C_C;ARG_4_C_C;ASP_5_C_C;PHE_6_C_C;GLY_7_C_C;SER_8_C_C;TRP_9_C_C;TYR_10_C_C;ALA_11_C_C,"ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A PHAGEDISPLAY 2 DERIVED PEPTIDE ANTAGONIST"
2JF9_A_P_39_1.pdb,2JF9,17283072,2.1,P03372,PF00104,1.10.565.10,A,215,P,13,S--PGSREWFKDMLS--,T--TTTHHHHHHHHC--,3--101220022103--,39,1,4,E--EEEEECCCCCCC--,7,6,D:0;E:0;I:0;K:0;L:0;Q:0;V:0;W:0,D:0;E:0;I:0;K:0;L:0;Q:0;V:0;W:0,A:3;D:2;E:5;G:1;H:1;K:3;L:3;M:2;N:2;P:3;Q:1;R:2;S:3;T:2;Y:3,A:10;C:3;D:8;E:8;F:6;G:9;H:10;I:11;K:4;L:33;M:12;N:5;P:4;Q:7;R:8;S:11;T:7;V:9;W:2;Y:1,H:0,H:0,C:8;G:1;H:19;T:8,C:17;E:9;G:5;H:123;T:14,39_1,D:0;E:1;I:1;K:1;L:3;Q:1;V:2;W:1,H:10,D:1;E:0;I:0;K:0;L:0;Q:0;V:0;W:0,H:1,6--555554444556--,ASP_47_A_EXOSITE;GLN_71_A_COREBINDING;GLU_76_A_COREBINDING;ILE_54_A_COREBINDING;LEU_50_A_COREBINDING;LEU_68_A_COREBINDING;LEU_75_A_COREBINDING;LYS_58_A_COREBINDING;TRP_79_A_COREBINDING;VAL_51_A_COREBINDING;VAL_72_A_COREBINDING,SPGSREWFKDMLS,0.679349962035024,0.558070590120588,7.08171335200741,9--999999999999--,SER_1_P_E;PRO_2_P_E;GLY_3_P_E;SER_4_P_E;ARG_5_P_E;GLU_6_P_E;TRP_7_P_C;PHE_8_P_C;LYS_9_P_C;ASP_10_P_C;MET_11_P_C;LEU_12_P_C;SER_13_P_C,"ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN 2 SPECIFIC PEPTIDE ANTAGONIST"
2OVH_A_B_39_1.pdb,2OVH,17356170,2.00,P06401,PF00104,1.10.565.10,A,243,B,13,G----LEAIIRKALMGK,H----HHHHHHHHHHHC,4----111101300334,39,1,4,E----EEECCCCCCCee,7,4,F:0;I:0;K:0;L:0;Q:0;S:0;V:0;W:0,F:0;I:0;K:0;L:0;Q:0;S:0;V:0;W:0,A:2;D:2;E:4;G:2;I:1;K:6;L:1;M:1;N:2;P:2;Q:4;R:4;S:6;T:3;V:2;Y:1,A:4;C:3;D:6;E:8;F:9;G:8;H:6;I:13;K:7;L:39;M:9;N:6;P:8;Q:13;R:6;S:17;T:6;V:10;W:3;Y:7,H:0;T:0,H:0;T:0,C:10;H:22;T:11,C:25;E:11;G:3;H:131;T:18,39_1,F:1;I:3;K:1;L:2;Q:2;S:1;V:1;W:0,H:10;T:1,F:0;I:0;K:0;L:0;Q:0;S:0;V:0;W:1,H:1;T:0,8----877656666899,GLN_67_A_COREBINDING;GLN_72_A_COREBINDING;ILE_64_A_COREBINDING;ILE_68_A_COREBINDING;ILE_71_A_COREBINDING;LEU_46_A_COREBINDING;LEU_47_A_COREBINDING;LYS_54_A_COREBINDING;PHE_59_A_COREBINDING;SER_53_A_COREBINDING;TRP_75_A_EXOSITE;VAL_50_A_COREBINDING,TNMGLEAIIRKALMGKY,0.203017832647462,0.176954732510288,10.2773254302858,9----999999999999,GLY_1_B_E;LEU_2_B_E;GLU_3_B_E;ALA_4_B_E;ILE_5_B_C;ILE_6_B_C;ARG_7_B_C;LYS_8_B_C;ALA_9_B_C;LEU_10_B_C;MET_11_B_C;GLY_12_B_e;LYS_13_B_e,"PROGESTERONE RECEPTOR WITH BOUND ASOPRISNIL AND A PEPTIDE 2 FROM THE COREPRESSOR SMRT"
4IUI_A_C_39_1.pdb,4IUI,23524984,2.30,P03372,PF00104,1.10.565.10,A,211,C,9,--K-----ILHRLLQD-,--C-----HHHHHHCC-,--3-----10221024-,39,1,4,--e-----CCCCCCCe-,7,1,D:0;E:0;I:0;L:0;M:0;N:0;Q:0;V:0,D:0;E:0;I:0;L:0;M:0;N:1;Q:0;V:0,A:3;C:1;D:1;E:4;G:1;H:2;K:2;L:3;M:1;N:1;P:1;R:1;S:5;T:1;Y:2,A:11;C:2;D:9;E:6;F:5;G:8;H:9;I:11;K:6;L:37;M:13;N:5;P:4;Q:8;R:9;S:9;T:6;V:9;W:3;Y:1,H:0,H:1,C:8;G:1;H:17;T:3,C:19;E:9;G:5;H:125;T:13,39_1,D:1;E:2;I:1;L:3;M:1;N:0;Q:1;V:1,H:10,D:0;E:0;I:0;L:0;M:0;N:0;Q:0;V:0,H:0,--5-----43554579-,ASN_48_A_exosite;ASP_205_A_COREBINDING;GLN_64_A_COREBINDING;GLU_209_A_COREBINDING;GLU_69_A_COREBINDING;ILE_47_A_COREBINDING;LEU_206_A_COREBINDING;LEU_61_A_COREBINDING;LEU_68_A_COREBINDING;MET_210_A_COREBINDING;VAL_65_A_COREBINDING,HKILHRLLQD,0.679640022041188,0.541354513040343,11.3519614604702,--9-----99999999-,LYS_1_C_e;ILE_2_C_C;LEU_3_C_C;HIS_4_C_C;ARG_5_C_C;LEU_6_C_C;LEU_7_C_C;GLN_8_C_C;ASP_9_C_e,"CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGANDBINDING DOMAIN 2 IN COMPLEX WITH DYNAMIC WAY DERIVATIVE 4A"
4ZUB_B_D_39_1.pdb,4ZUB,,2.39,,,1.10.565.10,B,227,D,9,-HK-----ILHRLLQ--,-CC-----HHHHHHC--,-51-----1023103--,39,1,4,-ee-----CCCCCCC--,7,2,A:0;D:0;E:0;I:0;K:0;L:0;M:0;N:0;Q:0;V:0,A:1;D:0;E:0;I:0;K:0;L:0;M:0;N:0;Q:0;V:0,A:1;D:3;E:4;F:1;G:1;H:1;K:2;L:4;M:1;N:4;P:1;Q:1;R:2;S:3;T:2;Y:4,A:12;C:3;D:8;E:7;F:5;G:9;H:11;I:11;K:5;L:37;M:13;N:4;P:5;Q:7;R:8;S:12;T:6;V:12;W:3,H:0,H:1,C:11;G:3;H:15;T:6,C:19;E:9;G:6;H:123;T:21,39_1,A:0;D:1;E:2;I:1;K:1;L:4;M:1;N:1;Q:1;V:1,H:13,A:0;D:0;E:0;I:0;K:0;L:0;M:0;N:0;Q:0;V:0,H:0,-65-----4455556--,ALA_227_B_exosite;ASN_52_B_COREBINDING;ASP_219_B_COREBINDING;GLN_68_B_COREBINDING;GLU_223_B_COREBINDING;GLU_73_B_COREBINDING;ILE_51_B_COREBINDING;LEU_220_B_COREBINDING;LEU_47_B_COREBINDING;LEU_65_B_COREBINDING;LEU_72_B_COREBINDING;LYS_55_B_COREBINDING;MET_224_B_COREBINDING;VAL_69_B_COREBINDING,HKILHRLLQDS,0.679550165273774,0.545447550160629,13.1571086109373,-99-----9999999--,HIS_1_D_e;LYS_2_D_e;ILE_3_D_C;LEU_4_D_C;HIS_5_D_C;ARG_6_D_C;LEU_7_D_C;LEU_8_D_C;GLN_9_D_C,"CRYSTAL STRUCTURE OF THE ERALPHA LIGANDBINDING DOMAIN Y537S IN 2 COMPLEX WITH OXABICYCLIC HEPTENE SULFONAMIDE OBHSN"
